New radioactive therapy shows promise in early trial for tough cancers

NCT ID NCT05723640

Completed Disease control Sponsor: Yantai LNC Biotechnology Singapore PTE. LTD. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-phase trial tested a new radioactive drug called 177Lu-LNC1004 in 11 adults with advanced solid tumors that had stopped responding to standard treatments. The drug targets a protein (FAP) found on many cancer cells, delivering radiation directly to the tumor. The main goals were to check safety and find the right dose for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 177Lu-LNC1004 (a radioactive drug that targets cancer cells)
What this could lead to: If successful, this could lead to a new treatment option for advanced solid tumors that have not responded to other therapies.
What could go wrong: This is a very early, small Phase 1 trial with only 11 participants, so results may not apply to everyone. The main goal is safety, not effectiveness, and there are risks from radiation exposure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR, UNSPECIFIED, ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR, UNSPECIFIED, ADULT

Contacts and locations

Locations

National University Cancer Institute, Singapore National University Hospital, Singapore.

Singapore, 119077, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.